Rabbit Recombinant Monoclonal CPT2 antibody. Carrier free. Suitable for WB, ICC/IF, IHC-P and reacts with Human, Mouse, Rat samples.
IgG
Rabbit
pH: 7.2 - 7.4
Constituents: PBS
Liquid
Monoclonal
WB | ICC/IF | IHC-P | |
---|---|---|---|
Human | Tested | Tested | Tested |
Mouse | Tested | Expected | Tested |
Rat | Tested | Expected | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species Mouse | Dilution info - | Notes - |
Species Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species Mouse | Dilution info - | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species Rat | Dilution info - | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Select an associated product type
Involved in the intramitochondrial synthesis of acylcarnitines from accumulated acyl-CoA metabolites (PubMed:20538056, PubMed:24780397). Reconverts acylcarnitines back into the respective acyl-CoA esters that can then undergo beta-oxidation, an essential step for the mitochondrial uptake of long-chain fatty acids and their subsequent beta-oxidation in the mitochondrion. Active with medium (C8-C12) and long-chain (C14-C18) acyl-CoA esters (PubMed:20538056).
Carnitine palmitoyltransferase II, CPT II, CPT1, CPT2
Rabbit Recombinant Monoclonal CPT2 antibody. Carrier free. Suitable for WB, ICC/IF, IHC-P and reacts with Human, Mouse, Rat samples.
Carnitine palmitoyltransferase II, CPT II, CPT1, CPT2
IgG
Rabbit
pH: 7.2 - 7.4
Constituents: PBS
Liquid
Monoclonal
Yes
EPR13626
Affinity purification Protein A
Blue Ice
+4°C
Do Not Freeze
ab231162 is the carrier-free version of Anti-CPT2 antibody [EPR13626] - C-terminal ab181114.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This supplementary information is collated from multiple sources and compiled automatically.
Carnitine palmitoyltransferase 2 (CPT2) also known as CPT-2 is an enzyme located mainly in the mitochondria of liver muscle and heart tissues. This enzyme has a molecular mass of approximately 68 kDa. CPT2 plays a mechanical role in the transfer of long-chain fatty acids from the cytosol into the mitochondrial matrix completing the process initiated by CPT1 on the outer mitochondrial membrane. CPT2 acts on the inner mitochondrial membrane converting acylcarnitine back into acyl-CoA which is an essential step in beta-oxidation. Expression of CPT2 is higher in tissues with elevated fatty acid oxidation rates.
CPT2 is integral to the mitochondrial pathway of fatty acid metabolism. It functions as part of the carnitine shuttle system a complex important for the conversion of acylcarnitine to acyl-CoA inside the mitochondria. This role is vital for the full oxidation of long-chain fatty acids. Through its action CPT2 aids in maintaining energy homeostasis and producing ketone bodies especially during periods of fasting or strenuous exercise.
CPT2 is involved in both the beta-oxidation and the carnitine shuttle pathways. These pathways facilitate the energy production from fatty acids particularly during states of low carbohydrate availability. CPT2 works closely with CPT1 as both enzymes form the gateway for the entry of long-chain fatty acids into mitochondria. Together with enzymes from the tricarboxylic acid cycle CPT2 helps sustain ATP production under such metabolic conditions.
Defects in CPT2 can lead to disorders like CPT2 deficiency which present with symptoms of muscle weakness and recurrent rhabdomyolysis especially during prolonged fasting or significant exercise. This deficiency can also result in hypoketotic hypoglycemia and liver dysfunction. CPT2-related disorders often involve altered interactions with proteins such as the acyl-CoA dehydrogenases impacting the normal fatty acid oxidation process and causing metabolic disturbances.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using the same antibody clone in a different buffer formulation (Anti-CPT2 antibody [EPR13626] - C-terminal ab181114).
Lanes 1- 2: Merged signal (red and green). Green - Anti-CPT2 antibody [EPR13626] - C-terminal ab181114 observed at 74 kDa. Red - Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) observed at 37 kDa.
Anti-CPT2 antibody [EPR13626] - C-terminal ab181114 was shown to react with CPT2/CPT1 in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line Human CPT2 knockout HeLa cell line ab265931 (knockout cell lysate Human CPT2 knockout HeLa cell lysate ab257180) was used. Wild-type HeLa and CPT2 knockout HeLa cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. Anti-CPT2 antibody [EPR13626] - C-terminal ab181114 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-CPT2 antibody [EPR13626] - C-terminal (Anti-CPT2 antibody [EPR13626] - C-terminal ab181114) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: CPT2 knockout HeLa cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 74 kDa
Observed band size: 74 kDa
Immunocytochemistry/Immunofluorescence analysis of MCF-7 (human breast carcinoma) cells labelling CPT2 with purified Anti-CPT2 antibody [EPR13626] - C-terminal ab181114 at 1/100. Cells were fixed with 100% methanol and permeabilized with 0.1% Triton X-100. Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077, Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody. The cells were co-stained with Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291, a mouse anti-tubulin antibody (1/1000) using Goat Anti-Mouse IgG H&L (Alexa Fluor® 594) preadsorbed ab150120, an Alexa Fluor® 594-conjugated goat anti-mouse IgG (1/1000) as the secondary. Nuclei couterstained with DAPI (blue).
For negative control 1, rabbit primary antibody was used, followed by anti-mouse secondary antibody (Goat Anti-Mouse IgG H&L (Alexa Fluor® 594) preadsorbed ab150120). For negative control 2, mouse primary antibody (Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291) was used followed by anti-rabbit secondary antibody (Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077).
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-CPT2 antibody [EPR13626] - C-terminal ab181114).
This WB data was generated using the same anti-CPT2 antibody clone, EPR13626, in a different buffer formulation (cat# Anti-CPT2 antibody [EPR13626] - C-terminal ab181114).
Lanes 1 - 4: Merged signal (red and green). Green - Anti-CPT2 antibody [EPR13626] - C-terminal ab181114 observed at 70 kDa. Red - loading control, Anti-GAPDH antibody [6C5] - Loading Control ab8245, observed at 37 kDa.
Anti-CPT2 antibody [EPR13626] - C-terminal ab181114 was shown to specifically react with CPT2 in wild-type HAP1 cells. No band was observed when CPT2 knockout samples were examined. Wild-type and CPT2/CPT1 knockout samples were subjected to SDS-PAGE. Anti-CPT2 antibody [EPR13626] - C-terminal ab181114 and Anti-GAPDH antibody [6C5] - Loading Control ab8245 (Mouse anti GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/10,000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776 secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-CPT2 antibody [EPR13626] - C-terminal (Anti-CPT2 antibody [EPR13626] - C-terminal ab181114) at 1/1000 dilution
Lane 1: Wild-type HAP1 whole cell lysate at 20 µg
Lane 2: CPT2 knockout HAP1 whole cell lysate at 20 µg
Lane 3: HeLa whole cell lysate at 20 µg
Lane 4: MCF7 whole cell lysate at 20 µg
Predicted band size: 74 kDa
Immunohistochemical analysis of paraffin embedded rat colon tissue section labelling CPT2 with purified Anti-CPT2 antibody [EPR13626] - C-terminal ab181114 at dilution of 1/50. The secondary antibody used was HRP-conjugated Goat Anti-Rabbit IgG H&L (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at dilution of 1/500. The sample was counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control and is shown in the inset.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-CPT2 antibody [EPR13626] - C-terminal ab181114).
Immunohistochemical analysis of paraffin embedded mouse kidney tissue section labelling CPT2 with purified Anti-CPT2 antibody [EPR13626] - C-terminal ab181114 at dilution of 1/50. The secondary antibody used was HRP-conjugated Goat Anti-Rabbit IgG H&L (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at dilution of 1/500. The sample was counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control and is shown in the inset.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-CPT2 antibody [EPR13626] - C-terminal ab181114).
This IHC data was generated using the same anti-CPT2 antibody clone, EPR13626, in a different buffer formulation (cat# Anti-CPT2 antibody [EPR13626] - C-terminal ab181114).
Immunohistochemical analysis of paraffin embedded human liver carcinoma tissue section labelling CPT2/CPT1 with purified Anti-CPT2 antibody [EPR13626] - C-terminal ab181114 at dilution of 1/50. The secondary antibody used was Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051), at a dilution of 1/500. The sample was counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control and is shown in the inset.
Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling CPT2 with unpurified Anti-CPT2 antibody [EPR13626] - C-terminal ab181114 at 1/100 dilution, followed by prediluted HRP Polymer for Rabbit IgG. Counter stained with Hematoxylin.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-CPT2 antibody [EPR13626] - C-terminal ab181114).
Immunohistochemical analysis of paraffin-embedded Human skeletal muscle tissue labeling CPT2 with unpurified Anti-CPT2 antibody [EPR13626] - C-terminal ab181114 at 1/100 dilution, followed by prediluted HRP Polymer for Rabbit IgG. Counter stained with Hematoxylin.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-CPT2 antibody [EPR13626] - C-terminal ab181114).
Immunofluorescent analysis of 4% paraformaldehyde-fixed MCF7 cells labeling CPT2 with unpurified Anti-CPT2 antibody [EPR13626] - C-terminal ab181114 at 1/100 dilution, followed by Goat anti rabbit IgG (Alexa Fluor® 488) secondary antibody at 1/200 dilution. Counter stained with Dapi.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-CPT2 antibody [EPR13626] - C-terminal ab181114).
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com